California Biotech Insights

John Fair is the President and CEO of J3 Bioscience, a biotechnology company reimagining how therapies are delivered through its proprietary intravaginal ring (IVR) platform to address some of the most persistent challenges in women’s health. With more than twenty years of leadership experience in women’s health, medical device and specialty pharmaceuticals, John has driven growth and innovation through senior roles in strategy, marketing, operations, and business development. He holds a Master’s degree from the University of Pennsylvania’s Perelman School of Medicine, a BA from Rider University, and has completed executive education in Mergers and Acquisitions at Stanford University Graduate School of Business.

Craig Parker is currently President & CEO of Surrozen (SRZN) , a biotechnology company pioneering the discovery and development of novel tissue specific antibodies that modulate the Wnt signaling pathway.  Since 2018, he has led the company’s growth from Series A to a public company with multiple first-in class clinical development candidates, a robust research pipeline, proprietary antibody technologies and a corporate partnership.   In establishing its industry leadership in the discovery of Wnt signaling therapeutics, Surrozen has filed more than 30 patent applications and published more than a dozen manuscripts in high impact journals related to its novel Wnt signaling mimetics.

Camilla Simpson is CEO and Board Member at Zehna Therapeutics. Camilla has over 25 years of US and International business and Research and Development strategy experience across a diverse group of organizations: from seed investments to public multi-national companies. Camilla has a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need. Her key accomplishments include the registration of Brineura® for CLN2 Batten’s Disease, Xagrid® for Essential Thrombocythemia, Fosrenol® for Hyperphosphatemia in CKD and Solaraze® for Actinic Keratosis. Prior to Zehna, Camilla founded Rare Strategic LLC where she provided strategic advice to early-stage venture-backed companies. Camilla has held numerous executive leadership positions, including SVP, Head of Product Portfolio Development at BioMarin Pharmaceutical Inc., Global Head of Regulatory Affairs at BioMarin Pharmaceutical Inc., and VP Global Regulatory Strategy- Early Development and Business Development at Shire Pharmaceuticals. At Shire she was part of the acquisition team for Movetis, Sarcode BioSciences, Ferrokin BioSciences and Advanced BioHealing. Camilla serves on the boards of Dyve Biosciences, GRI Biosciences and Spruce Biosciences. Camilla received a BSc from National University of Ireland, Galway, a BSc Hons, from Kingston University, UK, and an MSc with distinction from Birkbeck College, University of London.